Clinical Trials Browser

Terminated × Leukemia × Dasatinib × Clear all

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1/2 Terminated

32 enrolled 16 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02709083 2018-11-02

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Phase 2 Terminated

7 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2 Terminated

70 enrolled 8 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT00362466 2009-11-20

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Phase 3 Terminated

3 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase